Host‐Microbial Interactions in Idiopathic Pulmonary Fibrosis

Rationale: Changes in the respiratory microbiome are associated with disease progression in idiopathic pulmonary fibrosis (IPF). The role of the host response to the respiratory microbiome remains unknown. Objectives: To explore the host‐microbial interactions in IPF. Methods: Sixty patients diagnosed with IPF were prospectively enrolled together with 20 matched control subjects. Subjects underwent bronchoalveolar lavage (BAL), and peripheral whole blood was collected into PAXgene tubes for all subjects at baseline. For subjects with IPF, additional samples were taken at 1, 3, and 6 months and (if alive) 1 year. Gene expression profiles were generated using Affymetrix Human Gene 1.1 ST arrays. Measurements and Main Results: By network analysis of gene expression data, we identified two gene modules that strongly associated with a diagnosis of IPF, BAL bacterial burden (determined by 16S quantitative polymerase chain reaction), and specific microbial operational taxonomic units, as well as with lavage and peripheral blood neutrophilia. Genes within these modules that are involved in the host defense response include NLRC4, PGLYRP1, MMP9, and DEFA4. The modules also contain two genes encoding specific antimicrobial peptides (SLPI and CAMP). Many of these particular transcripts were associated with survival and showed longitudinal overexpression in subjects experiencing disease progression, further strengthening the relationship of the transcripts with disease. Conclusions: Integrated analysis of the host transcriptome and microbial signatures demonstrated an apparent host response to the presence of an altered or more abundant microbiome. These responses remained elevated in longitudinal follow‐up, suggesting that the bacterial communities of the lower airways may act as persistent stimuli for repetitive alveolar injury in IPF.

[1]  A. Aceti,et al.  α‐Defensin increase in peripheral blood mononuclear cells from patients with hepatitis C virus chronic infection , 2006, Journal of viral hepatitis.

[2]  Hao Xu,et al.  The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus , 2011, Nature.

[3]  Jong-Min Song,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome , 2010, European Respiratory Journal.

[4]  S. Johnston,et al.  Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[5]  Naping Li,et al.  Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta. , 2009, Toxicology letters.

[6]  I. Noth,et al.  Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. , 2013, JAMA.

[7]  M. Nakazato,et al.  Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis. , 2002, Thorax.

[8]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Peter Langfelder,et al.  Eigengene networks for studying the relationships between co-expression modules , 2007, BMC Systems Biology.

[10]  G. Laurent,et al.  Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis , 2016, Laboratory Investigation.

[11]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[12]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[13]  Ivana V. Yang,et al.  A common MUC5B promoter polymorphism and pulmonary fibrosis. , 2011, The New England journal of medicine.

[14]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[15]  Meilan K. Han,et al.  Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. , 2014, The Lancet. Respiratory medicine.

[16]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[17]  Jin Woo Song,et al.  Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[18]  Ivana V. Yang,et al.  Muc5b is required for airway defence , 2013, Nature.

[19]  Naftali Kaminski,et al.  Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. , 2013, The Lancet. Respiratory medicine.

[20]  E. Chilvers,et al.  Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial , 2012, Thorax.

[21]  T. Maher,et al.  The role of infection in the pathogenesis of idiopathic pulmonary fibrosis , 2013, European Respiratory Review.

[22]  J. Farrar,et al.  Human TOLLIP Regulates TLR2 and TLR4 Signaling and Its Polymorphisms Are Associated with Susceptibility to Tuberculosis , 2012, The Journal of Immunology.

[23]  Murali M. Yallapu,et al.  Curcumin nanoformulations: a future nanomedicine for cancer. , 2012, Drug discovery today.

[24]  A. Kulkarni,et al.  Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing , 2000, Nature Medicine.

[25]  Daniel R. Salomon,et al.  Strategies for aggregating gene expression data: The collapseRows R function , 2011, BMC Bioinformatics.

[26]  C. Owen,et al.  Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. , 2015, American journal of respiratory cell and molecular biology.

[27]  Elissa Murphy,et al.  The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. , 2014, American journal of respiratory and critical care medicine.

[28]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[29]  R. Hubbard,et al.  The rising incidence of idiopathic pulmonary fibrosis in the UK , 2011, Thorax.

[30]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[31]  K. Fukase,et al.  Human peptidoglycan recognition protein S is an effector of neutrophil-mediated innate immunity. , 2005, Blood.

[32]  I. Noth,et al.  A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[33]  Ivana V. Yang,et al.  Gene expression profiling of familial and sporadic interstitial pneumonia. , 2007, American journal of respiratory and critical care medicine.

[34]  G. Laurent,et al.  Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? , 2007, European Respiratory Journal.

[35]  Y. Wang,et al.  Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kappaB in mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[36]  George C Tseng,et al.  Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis , 2013, Science Translational Medicine.

[37]  S. Horvath,et al.  Variations in DNA elucidate molecular networks that cause disease , 2008, Nature.